Literature DB >> 29158190

Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Renato M Lupinacci1, Anastasia Goloudina2, Olivier Buhard3, Jean-Baptiste Bachet4, Raphaël Maréchal5, Pieter Demetter6, Jérôme Cros7, Armelle Bardier-Dupas8, Ada Collura9, Pascale Cervera10, Aurélie Scriva11, Sylvie Dumont12, Pascal Hammel13, Alain Sauvanet14, Christophe Louvet15, Jean-Robert Delpéro16, François Paye17, Jean-Christophe Vaillant18, Thierry André19, Jean Closset5, Jean-François Emile20, Jean-Luc Van Laethem5, Vincent Jonchère3, Issam Abd Alsamad21, Martine Antoine22, Anita Rodenas22, Jean-François Fléjou10, Nelson Dusetti23, Juan Iovanna23, Alex Duval24, Magali Svrcek25.   

Abstract

Microsatellite instability (MSI) caused by mismatch repair deficiency (dMMR) is detected in a small proportion of pancreatic ductal adenocarcinomas (PDACs). dMMR and MSI have been associated with responses of metastatic tumors, including PDACs, to immune checkpoint inhibitor therapy. We performed immunohistochemical analyses of a 445 PDAC specimens, collected from consecutive patients at multiple centers, to identify those with dMMR, based on loss of mismatch repair proteins MLH1, MSH2, MSH6, and/or PMS2. We detected dMMR in 1.6% of tumor samples; we found dMMR in a larger proportion of intraductal papillary mucinous neoplasms-related tumors (4/58, 6.9%) than non- intraductal papillary mucinous neoplasms PDAC (5/385, 1.3%) (P = .02). PDACs with dMMR contained potentially immunogenic mutations because of MSI in coding repeat sequences. PDACs with dMMR or MSI had a higher density of CD8+ T cells at the invasive front than PDACs without dMMR or MSI (P = .08; Fisher exact test). A higher proportion of PDACs with dMMR or MSI expressed the CD274 molecule (PD-L1, 8/9) than PDACs without dMMR or MSI (4/10) (P = .05). Times of disease-free survival and overall survival did not differ significantly between patients with PDACs with dMMR or MSI vs without dMMR or MSI. Studies are needed to determine whether these features of PDACs with dMMR or MSI might serve as prognostic factors.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytokine Production; Marker; Pancreatic Cancer; T-cell Activation

Mesh:

Substances:

Year:  2017        PMID: 29158190     DOI: 10.1053/j.gastro.2017.11.009

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  28 in total

1.  Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites.

Authors:  Claudio Luchini; Andrea Mafficini; Deyali Chatterjee; Maria L Piredda; Concetta Sciammarella; Pooja Navale; Giuseppe Malleo; Paola Mattiolo; Giovanni Marchegiani; Antonio Pea; Roberto Salvia; Lodewijk A Brosens; Gaetano Paolino; Maria G Mastrosimini; Nicola Silvestris; Michele Milella; Liang Cheng; Volkan N Adsay; Rita T Lawlor; Aldo Scarpa
Journal:  Virchows Arch       Date:  2021-10-06       Impact factor: 4.064

2.  Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception.

Authors:  Sharia Hernandez; Edwin Roger Parra; Luisa M Solis; Subrata Sen; Naohiro Uraoka; Ximing Tang; Yu Shen; Wei Qiao; Mei Jiang; Shanyu Zhang; Barbara Mino; Wei Lu; Renganayaki Pandurengan; Cara Haymaker; Kajsa Affolter; Courtney L Scaife; Michele Yip-Schneider; C Max Schmidt; Matthew A Firpo; Sean J Mulvihill; Eugene J Koay; Huamin Wang; Ignacio I Wistuba; Anirban Maitra
Journal:  Clin Cancer Res       Date:  2022-05-02       Impact factor: 13.801

Review 3.  Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.

Authors:  Vinod P Balachandran; Gregory L Beatty; Stephanie K Dougan
Journal:  Gastroenterology       Date:  2019-01-18       Impact factor: 22.682

Review 4.  New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.

Authors:  Ritu Raj Singh; Eileen M O'Reilly
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

Review 5.  Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies.

Authors:  Jimmy A Guo; Hannah I Hoffman; Colin D Weekes; Lei Zheng; David T Ting; William L Hwang
Journal:  Clin Cancer Res       Date:  2021-03-02       Impact factor: 12.531

Review 6.  Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features.

Authors:  Eva Karamitopoulou
Journal:  Br J Cancer       Date:  2019-05-21       Impact factor: 7.640

7.  Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms.

Authors:  Bo Huang; Maria A Trujillo; Kohei Fujikura; Miaozhen Qiu; Fei Chen; Matthäus Felsenstein; Cancan Zhou; Michael Skaro; Christian Gauthier; Anne Macgregor-Das; Danielle Hutchings; Seung-Mo Hong; Ralph H Hruban; James R Eshleman; Elizabeth D Thompson; Alison P Klein; Michael Goggins; Laura D Wood; Nicholas J Roberts
Journal:  J Pathol       Date:  2020-09-19       Impact factor: 9.883

8.  Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma.

Authors:  Neha R Patil; Gazala N Khan
Journal:  Am J Case Rep       Date:  2020-07-13

Review 9.  Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer.

Authors:  Bilikis Aderonke Abolarinwa; Ridwan Babatunde Ibrahim; Yen-Hua Huang
Journal:  Int J Mol Sci       Date:  2019-09-18       Impact factor: 5.923

10.  Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications.

Authors:  Claudio Luchini; Lodewijk A A Brosens; Laura D Wood; Deyali Chatterjee; Jae Il Shin; Concetta Sciammarella; Giulia Fiadone; Giuseppe Malleo; Roberto Salvia; Valentyna Kryklyva; Maria L Piredda; Liang Cheng; Rita T Lawlor; Volkan Adsay; Aldo Scarpa
Journal:  Gut       Date:  2020-04-29       Impact factor: 31.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.